News

An ongoing Phase 1b trial of VY-AADC01, a gene therapy for the treatment of advanced Parkinson’s disease (PD), is showing positive results, including improvement of motor function and activities of daily living, durable clinical effects, and good tolerability. The announcement was made by Voyager Therapeutics, the gene therapy company specialized…

Sumitomo Dainippon Pharma has asked Japanese authorities to approve its Trerief (zonisamide) as a new therapy for parkinsonism in dementia patients with Lewy bodies, the company announced in a press release. Trerief went on sale in Japan in March 2009 as a treatment for Parkinson’s patients who saw insufficient…

Oral health is essential for everyone, but people living with Parkinson’s disease need to pay particular attention to their mouth, teeth and gums to limit any problems. MORE: Three causes of psychosis in Parkinson’s disease According to the National Parkinsons Foundation, Parkinson’s disease can affect oral health in a number of…

In an unexpected finding, researchers demonstrated that certain asthma drugs might protect from developing Parkinson’s disease by lowering the production of the disease-linked protein alpha-synuclein. But researchers caution against attempting to medicate with such drugs before clinical trials establish they are safe in this patient group, and that they really…

AstraZeneca has partnered with Takeda Pharmaceutical to develop and commercialize the alpha-synuclein antibody MEDI1341 for the treatment of Parkinson’s disease. MEDI1341 is expected to enter a Phase 1 clinical trial later this year. Under the terms of the agreement, AstraZeneca will supervise…

Researchers in Japan are preparing for a first human trial of induced pluripotent stem cells (iPSCs) in patients with Parkinson’s disease, after obtaining promising data from a study in monkeys. The study, which appeared in the journal Nature, demonstrated that transplanting human iPSCs into the brains of the primate…

The U.S. Food and Drug Administration (FDA) has given a green light to Titan Pharmaceuticals to begin a first-in-human clinical trial testing an implant that provides continuous release of ropinirole to treat Parkinson’s signs and symptoms. In the open-label Phase 1/2 trial (NCT03250117), which is now recruiting, roughly 20 Parkinson’s…

The U.S. Food and Drug Administration (FDA) will not process Acorda Therapeutics‘ marketing application for Inbrija (CVT-301), intended for the treatment of off-periods in Parkinson’s disease, until certain questions are answered. The FDA’s refusal to accept Acorda’s new drug application (NDA) for Inbrija wasn’t based on safety or efficacy concerns,…

Synthetic 3D protein structures that better mimic those in nature, but are simpler, could help scientists investigate several disorders, including Parkinson’s disease, a study indicates. The research, “Supramolecular Multiblock Copolymers Featuring Complex Secondary Structures,” appeared in the Journal of the American Chemical Society. Dr. Marcus…

Singapore’s National Neuroscience Institute (NNI) and Nanyang Technological University (NTU Singapore) are teaming up to develop new technologies to better diagnose and treat patients with Parkinson’s disease, brain injuries and other neurological conditions. The collaboration aims to develop an artificial intelligence system capable of using computed tomography (CT) scans to accurately…